Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 11/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3346853 | 0.85 | FGFR3 (0.48) | FGFR3ADORA2AADORA1 | |
| SCHEMBL3346457 | 0.84 | FGFR3 (0.38) | FGFR3ADORA2AADORA1 | |
| SCHEMBL1126337 | 0.84 | FGFR3 (0.42) | FGFR3HRH3KDRADORA2AADORA1 | |
| SCHEMBL1126140 | 0.82 | HRH3 (0.53) | FGFR3HRH3KDRMAPTHSD17B10 | |
| SCHEMBL3348914 | 0.82 | FGFR3 (0.42) | FGFR3PTGES | |
| SCHEMBL1126565 | 0.82 | FGFR3 (0.45) | FGFR3PTGESMAPTHSD17B10 | |
| SCHEMBL1127069 | 0.81 | FGFR3 (0.49) | FGFR3KDRPTGES | |
| SCHEMBL3316168 | 0.73 | MYC (0.43) | FGFR3MAPTHSD17B10 | |
| SCHEMBL3352031 | 0.71 | FGFR3 (0.72) | FGFR3 | |
| SCHEMBL17023123 | 0.71 | HRH3 (0.52) | HRH3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | FGFR3 1515/4885HRH3 706/4885KDR 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.